BAL3833 / Basilea - LARVOL DELTA

CRUK scientists develop drug that targets KRAS pathways (PharmaTimes) - "According to the researchers, CCT3833 was able to restrict the growth of cancer cells and was more effective in killing the cancer cells compared to other KRAS inhibitors...In mouse models of KRAS mutated pancreatic cancer, the drug was also more effective than other KRAS inhibitors in preventing cancer growth and also reduced tumour size."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Pancreatic Cancer

Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019 (GlobeNewswire) - "...Basilea is also planning to start a phase 1/2 study in gastric cancer by Q3 2020...Basilea has concluded patient enrolment into two early-stage clinical studies with lisavanbulin (formerly BAL101553). The studies explored once-daily oral lisavanbulin in patients with recurrent glioblastoma or high grade glioma (phase 1 study)...The study is anticipated to start mid-2020...a phase 1 study is ongoing in the U.S. in newly diagnosed glioblastoma patients with first-line treatment of oral lisavanbulin in combination with radiotherapy. This study could complete patient enrolment by mid-2020...The first-in-human phase 1 study with the panRAF/SRC kinase inhibitor BAL3833 in patients with advanced solid tumors did not result in the determination of a maximum tolerated dose. Therefore, Basilea entered into pre-clinical reformulation work..."

Enrollment status • Pipeline update • Trial initiation date

A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours (clinicaltrials.gov) - P1; N=31; Completed; Sponsor: Royal Marsden NHS Foundation Trust; Active, not recruiting ➔ Completed; N=69 ➔ 31; Trial completion date: Mar 2019 ➔ Jul 2018

Clinical • Enrollment change • Trial completion • Trial completion date